Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04848064
Title Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors John Reneau
Indications

adult T-cell leukemia

cutaneous T cell lymphoma

Therapies

Cyclophosphamide + Fludarabine

Mogamulizumab

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.